Efzofitimod Phase 3 FDA Alignment: First-Mover Bet in Sarcoidosis With No Mechanistic Roadmap

aTyr Pharma Aligns with FDA on Efzofitimod Phase 3 for Pulmonary Sarcoidosis

aTyr Pharma has reached alignment with the U.S. Food and Drug Administration (FDA) on the protocol for a global Phase 3 study of its lead therapeutic candidate, efzofitimod. This study will target patients with chronic, symptomatic pulmonary sarcoidosis with restrictive lung disease. The company anticipates initiating study-related activities in the fourth quarter of 2026, with a focus on regulatory submissions in the U.S. and Europe. The 54-week, randomized, double-blind, placebo-controlled trial plans to enroll up to approximately 372 patients, evaluating 5.0 mg/kg efzofitimod administered intravenously every three weeks. The primary endpoint is the change from baseline in forced vital capacity (FVC) at week 48.

• aTyr Pharma has successfully aligned with the U.S. FDA on the protocol for its planned global Phase 3 study of efzofitimod in pulmonary sarcoidosis. This critical regulatory milestone enables the company to proceed with initiating study-related activities in the fourth quarter of 2026, with a strategic focus on subsequent regulatory submissions in both the U.S. and Europe.
• The upcoming Phase 3 trial is designed as a global, randomized, double-blind, placebo-controlled study spanning 54 weeks. It aims to enroll approximately 372 patients suffering from moderate to severe pulmonary sarcoidosis with restrictive lung disease, who are on stable doses of corticosteroids or immunosuppressants. Patients will be randomized to receive either 5.0 mg/kg efzofitimod or placebo intravenously every three weeks for 17 doses.
• The primary efficacy endpoint for the study is the change from baseline in forced vital capacity (FVC) at week 48, a crucial measure of lung function. A key secondary endpoint will assess the change in the King’s Sarcoidosis Questionnaire (KSQ)-Lung score at week 48. This design is informed by positive subgroup analysis data from the Phase 3 EFZO-FIT™ study, which demonstrated clinically meaningful FVC benefits and improved patient-reported outcomes in a similar patient population.

Navigating the Evolving Pulmonary Sarcoidosis Treatment Landscape

The traditional corticosteroid-centred paradigm for pulmonary sarcoidosis has faced meaningful challenge from recent trial data. A prospective trial demonstrated that initial treatment with methotrexate is noninferior to prednisone with regard to the change from baseline to week 24 in the percentage of predicted forced vital capacity (FVC), and differences in the side-effect profiles between the two agents now actively inform shared decision-making. A high-dose prednisolone regimen (40 mg) was shown to be no superior to a lower dose (20 mg) in improving outcomes or health-related quality of life, and was associated with similar adverse effects — further eroding the rationale for aggressive corticosteroid escalation. Together, these findings support a paradigm shift that moves away from corticosteroids as the default first-line approach.

Beyond first-line therapy, a systematic review and meta-analysis encompassing 16 studies — 8 randomised controlled trials and 8 single-arm trials — quantified the benefit of biologic and targeted synthetic therapies. Meta-analysis of %-predicted FVC showed a modest improvement with treatment (mean change: 4.79%, 95% CI 1.22 to 8.35), driven primarily by anti-TNF trials (5.70%, 95% CI 1.61 to 9.78), though heterogeneity was substantial (I²=76.3%). Vote counting across all estimates identified infliximab, adalimumab, efzofitimod, and tofacitinib as demonstrating a positive direction of effect, with the caveat that improvements in several outcomes did not reach thresholds for minimal clinically important differences. A separate meta-analysis of anti-TNF-α agents specifically reported a combined overall treatment success rate of 69.9% (95% CI 35.0–90.9) in pulmonary sarcoidosis and 74.5% (95% CI 36.3–93.7) in extrapulmonary disease, with high heterogeneity (I²: 70% and 90%, respectively).

For the subset of patients whose disease evolves into a progressive fibrosing phenotype, the antifibrotic nintedanib has entered clinical consideration. A network meta-analysis of randomised controlled trials in progressive fibrotic interstitial lung diseases identified budesonide as improving lung function specifically in pulmonary sarcoidosis, while pirfenidone and nintedanib were effective in slowing progression and reducing mortality across the broader PF-ILD population. Notably, a systematic review and meta-analysis found that the annual FVC decline benefit with nintedanib did not reach statistical significance in the fibrotic sarcoidosis subgroup (mean difference: −20.5 ml/yr; 95% CI −337.1 to 296.1 ml/yr) compared with placebo, underscoring that evidence specific to fibrotic sarcoidosis remains limited. Across all these emerging treatment categories, small sample sizes and heterogeneity in study design continue to constrain definitive conclusions, reinforcing the need for large, high-quality randomised controlled trials in well-defined sarcoidosis populations.

Addressing Unmet Needs in Restrictive Pulmonary Sarcoidosis

Pulmonary sarcoidosis with restrictive lung disease presents a complex therapeutic landscape, where the transition from inflammatory to fibrotic disease in approximately 10–20% of chronic cases significantly narrows available treatment options. The absence of a standardized treatment protocol, compounded by the heterogeneity of disease course and organ involvement, creates persistent challenges for clinical decision-making.

• Corticosteroid dependency and cumulative toxicity. Oral corticosteroids remain the cornerstone of sarcoidosis therapy and are highly likely to be effective over a relatively short period, but sarcoidosis is often a chronic condition, making long-term corticosteroid use associated with significant cumulative toxicity. This necessitates corticosteroid-sparing strategies, yet 20–40% of patients are refractory to commonly used agents — including methotrexate, cyclophosphamide, azathioprine, and mycophenolate mofetil — or develop severe adverse events on these therapies.

• Limited and inconsistent evidence for TNF antagonists. TNF antagonists, predominantly infliximab, represent a second-line option in refractory sarcoidosis, but the evidence base remains insufficient to ensure their efficacy. In a multicenter study of 132 patients, the overall clinical response rate was 64%, while adverse events were observed in 52% of patients — including infections (36%) and allergic reactions (8%) — requiring treatment interruption in 23% of cases. A systematic review similarly concluded there is insufficient evidence to ensure efficacy, and that a careful evaluation of the benefit/risk ratio must be considered on an individual basis before initiating infliximab.

• Risk of paradoxical drug-induced sarcoidosis. Anti-TNF-alpha agents carry the risk of inducing paradoxical inflammation manifesting as sarcoid-like granulomatosis with noncaseating granulomas. This complicates the therapeutic calculus, as the same drug class used to manage refractory inflammatory disease can itself precipitate pulmonary sarcoidosis, requiring careful and ongoing monitoring of patients on biological therapy.

• Unmet need once fibrosis is established. In the subset of patients who progress to fibrotic pulmonary sarcoidosis, pathogenetic mechanisms remain poorly understood and clinical management is particularly challenging. While nintedanib has shown a positive effect on non-IPF fibrotic lung diseases including fibrotic sarcoidosis, other antifibrotic drugs remain under investigation. The greatest challenge is identifying effective antifibrotic therapies once fibrosis develops, as granulomas can persist and serve as a nidus for fibrosis growth sustained by fibrosis-stimulating cytokines.

• Emerging but unvalidated targeted therapies. Constitutive activation of JAK-STAT signaling — driven by elevated pro-inflammatory cytokines including IL-8, IL-12, IL-6, and TNF-α — has identified JAK inhibition as a promising strategy, and case series have reported a positive effect of tocilizumab in refractory disease. However, these approaches remain investigational, and more treatment options are expected but not yet established for routine clinical use.

Key Design Elements of the Efzofitimod Phase 3 Study

Several trials have evaluated therapeutic interventions in pulmonary sarcoidosis, spanning corticosteroid protocols, biologic agents, and endothelin receptor antagonists. The studies below represent key designs addressing lung function, safety, and quality of life in this population.

Efzofitimod's Broader Potential Beyond Pulmonary Sarcoidosis

The knowledge base does not have sufficient information to answer this question.

Charting a New Course for Chronic Pulmonary Sarcoidosis Treatment

The recent alignment with the FDA on the Phase 3 protocol for efzofitimod represents a pivotal moment for patients suffering from chronic, symptomatic pulmonary sarcoidosis. This condition, characterized by granuloma formation and often leading to restrictive lung disease, currently relies heavily on corticosteroids like prednisone. While effective in managing acute inflammation, long-term steroid use carries a heavy burden of side effects, and studies indicate that the correlation between prednisone dose and FVC improvement is not always clear, often necessitating high cumulative doses.

Efzofitimod offers a distinct approach. As a first-in-class biologic, it targets neuropilin-2 (NRP2), a receptor highly expressed in sarcoidosis granulomas and on immune cells during lung inflammation. By modulating NRP2, efzofitimod aims to downregulate immune responses, inhibit proinflammatory pathways, and reduce inflammation and fibrosis. Early clinical data from a Phase 1b/2a study showed promising dose-dependent improvements in steroid reduction, patient-reported quality of life, and trends toward improved lung function, alongside a favorable safety and tolerability profile. A post-hoc analysis further indicated that therapeutic doses were associated with a lower rate of relapse during corticosteroid tapering and increased forced vital capacity.

This global Phase 3 study, enrolling up to 372 patients and focusing on FVC change as its primary endpoint, is designed to definitively establish efzofitimod's efficacy and safety. Success could position it as a much-needed steroid-sparing, disease-modifying therapy, potentially transforming the treatment landscape for pulmonary sarcoidosis. However, the trial must rigorously confirm the efficacy signals observed in earlier, smaller studies, particularly the FVC improvements, and thoroughly characterize the long-term safety profile in a larger patient cohort. Demonstrating a clear benefit over existing standards of care will be crucial for broad adoption and market penetration. Beyond sarcoidosis, a positive outcome could also validate the NRP2 modulation platform, opening doors for efzofitimod's application in other interstitial lung diseases where inflammation and fibrosis are key drivers.